Chaste tree for PCOS

Verdict: Weak, disputed evidence for PCOS

The evidence that chaste tree (Vitex agnus-castus) helps polycystic ovary syndrome is weak and disputed: a handful of small, mostly Iranian trials hint at modest benefit for menstrual regularity and metabolic markers, but no major guideline, regulator, or clinic endorses it for PCOS, so it should not be relied on as a treatment.

C 🟠 C Weak Evidence Disputed

🔬Why this grade7-layer evidence engine

The direct human evidence is thin and comes almost entirely from small single-center Iranian trials. Only one placebo-controlled RCT specifically studied PCOS (PMID 41428718, n=60, 12 weeks), reporting modest improvements in antioxidant capacity, HDL, insulin resistance (HOMA-IR), and menstrual frequency. The remaining trials compared chaste tree against active drugs rather than placebo: PMID 28208942 (n=120) found it comparable to metformin for irregular cycles with fewer side effects, and review articles (PMID 31741280, PMID 25524718) describe lowered LH, prolactin, and testosterone but explicitly call for higher-quality studies.

Crucially, mainstream authorities are silent on PCOS specifically. The WHO supports chaste tree only for PMS, hyperprolactinaemia, luteal insufficiency, and cyclic mastalgia, and EU regulators recognize a well-established use solely for PMS at around 20 mg/day. The US FDA has issued warning letters treating disease claims for Vitex products as illegal, and the Mayo Clinic mentions chasteberry only for PMS while noting few studies show herbs work; it does not address PCOS at all.

Together this is a textbook weak-evidence, disputed picture: a plausible hormonal mechanism plus a few small positive trials, but no large or Western trials and no guideline or specialist endorsement for PCOS. Doses and preparations vary widely, drug interactions (notably with oral contraceptives) are a concern for this population, and it must be avoided in pregnancy. People with PCOS should treat chaste tree as unproven for this condition and prioritize guideline-backed options under medical supervision.

⚖️

Scoring transparency

All scores computed by a 7-layer evidence engine — fully auditable
Raw score 0.48
D
C
B
A
S
← counter-evidence / ineffectiveeffective / strong evidence →
Final grade
C · Disputed
Confidence
67%
Broadly consistent
Evidence level
E3
Single high-quality meta-analysis

How strongly each layer supports this effect

lower = less supportive
L2 PubMedPrimary literature
0.45
L3 MechanismPlausibility
0.45
L1 ExamineGlobal benchmark
0.50
L11 AI re-checkIndependent read
0.50
L5 Clinical bodiesAuthoritative stance
0.55
Against Mixed Supports
View the full decision path (audit trail)
  1. compute_raw_score — 加權公式: L2×0.30 + L3×0.25 + L5×0.25 + L11×0.10 + L1×0.10 = 0.485
  2. tier_from_score — 依分數區間映射至 tier letter
  3. apply_hec_rules — 無高階證據可裁決
  4. tier_strict_requirement_check — Tier 條件達標,未降階
  5. detect_disputes — 偵測到 1 個 hard + 0 個 soft dispute
  6. decide_status — 依 tier + dispute 結果決定 status

📄PubMed studies (5)L2 · primary research & systematic reviews

The Effect of Vitex Agnus-Castus Plant on Some Markers of Oxidative Stress, Lipid Profile and Insulin Resistance in Women with Polycystic Ovary Syndrome: A Randomized, Double-Blind Controlled Clini…
PMID: 41428718 2026 RCT (double-blind) n = 60
Finding: Vitex significantly increased total antioxidant capacity (effect 13.01, p<0.05) and glutathione peroxidase (3.35, p<0.05), increased HDL (5.74, p<0.05), decreased oxidative stress index (-9.30, p<0.05) and HOMA-IR (-0.31, p<0.05), and improved menstrual frequency (3.51, p<0.05) vs placebo.
Effect size: TAC +13.01; HOMA-IR -0.31; menstrual frequency +3.51 (all p<0.05)
View on PubMed
Comparing the Effects of Agnugol and Metformin on Oligomenorrhea in Patients with Polycystic Ovary Syndrome: A Randomized Clinical Trial
PMID: 28208942 2016 RCT (open-label) n = 120
Finding: Agnugol and metformin showed comparable effects on menstrual cycle regulation, menstruation length and pad use in PCOS-related oligomenorrhea; metformin group reported substantially more adverse effects (loss of appetite, nausea, vomiting) vs none in Agnugol group. Specific p-values not reported in abstract.
View on PubMed
A comprehensive review of clinical studies with herbal medicine on polycystic ovary syndrome (PCOS)
PMID: 31741280 2019 系統性回顧
Finding: Review concludes Vitex agnus-castus can impact menstrual and ovulatory dysfunctions in PCOS; included RCTs report comparable efficacy to metformin (oligomenorrhea) and to low-dose OCPs (menstrual normalization, prolactin, free testosterone), with better tolerability. Authors stress further high-quality trials needed.
View on PubMed
Herbal medicine for the management of polycystic ovary syndrome (PCOS) and associated oligo/amenorrhoea and hyperandrogenism; a review of the laboratory evidence for effects with corroborative clin…
PMID: 25524718 2014 Other
Finding: Across reviewed clinical studies, herbal interventions including Vitex agnus-castus reduced luteinising hormone, prolactin, fasting insulin and testosterone; evidence for regulation of ovulation, improved metabolic hormone profile and improved fertility outcomes in PCOS. Vitex equivalent to bromocriptine for prolactin lowering. Per-Vitex PCOS sample sizes not isolated in abstract.
🟠 Limited quality
View on PubMed
The Effects of Combined Low-Dose Oral Contraceptives and Vitex Agnus on the Improvement of Clinical and Paraclinical Parameters of Polycystic Ovarian Syndrome: A Triple-Blind, Randomized, Controlle…
PMID: 2016 RCT (double-blind) n = 70
— See PubMed for details
View on PubMed

🏛️Regulatory & authoritative positionsL4/L5 · FDA / EMA / NIH ODS / Cochrane / Mayo …

L4a US FDA
Cautious
Doctors use Vitex [an ingredient in FertilHerb for Women] to treat mild endometriosis or prevent its advancement. It has also been effective in treating amenorrhea, which is the lack of menstruation, as well as irregular menstruation, which can hinder fertility greatly. source↗
L4b EU EFSA
Cautious
L4d TW TFDA / 衛福部
Neutral
西洋牡荊(外文名稱 Chaste Berry,學名 Vitex agnus-castus L.)列於食藥署「可供食品使用原料彙整一覽表」,分類為草、木本植物類(1),使用部位為果實;備註欄無特殊使用限量或警語。本平台非屬正面表列,未列載者亦非不得作為食品原料使用。 source↗
L4e WHO
Supportive
Uses supported by clinical data: Orally for the symptomatic treatment of gynaecological disorders including corpus luteum insufficiency and hyperprolactinaemia, premenstrual syndrome, menstrual irregularities, cyclic mastalgia and also to treat hormonally-induced acne. Contraindications: Fructus Agni Casti should not be used during pregnancy. Nursing mothers: ...the use of the crude drug by nur… source↗
L5a NIH Office of Dietary Supplements
Cautious
L5c Cleveland Clinic
Neutral
L5e Specialty Society (condition-mapped)
Not addressed
PMID 100% verifiedevery citation checked via NCBI Entrez
🔬5 PubMed studiesindependently re-checked by multiple sub-agents
engine_version: v1.0 claim_id: CLM-COND-pcos-INT-vitex-001 繁體中文版 →